ReviewFrontiers in pharmacology2020
Therapeutic Potential of
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 317 citations in OpenAlex.
- Trial
- Effects of Long-Term Supplementation withNutrients · 2026Trial
- Efficacy and safety ofFrontiers in pharmacology · 2025Trial
- Efficacy and Tolerability of a Novel Cosmetic and Over-the-Counter Facial Acne Regimen Versus a Prescription Treatment.Journal of cosmetic dermatology · 2025Trial
- Therapeutic potential ofPharmaceutical biology · 2026Review
- The potential of plant-derived exosome-like nanovesicles fromFuture science OA · 2026Article
- Serum-based untargeted metabolomics reveals the therapeutic mechanism of asiatic acid against atherosclerosis in ApoENaunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Depression-Related Mechanistic and Translational Evidence forLife (Basel, Switzerland) · 2026Review
- Validated HPLC Method for Simultaneous Quantification of Six Triterpenes with Isomer Separation in CommercialACS omega · 2026Article
- Targeting oxidative stress, senescence, and neurodegeneration: anti-aging perspectives of Urtica dioica and Centella asiatica.Inflammopharmacology · 2026Review
- Centella Asiatica Alleviates Type 2 Diabetes-Related Hepatic Glycolipid Disorders via Regulating UPP1-Mediated Pyrimidine Metabolism.Current issues in molecular biology · 2026Article
- Review
- Modular reconstruction and multilevel regulation ofSynthetic and systems biotechnology · 2026Article
- Unlocking the Power of Plant-Derived Natural Products: Therapeutic Benefits for Cognitive Health and Neuropsychiatric Symptoms in Dementia-Related Diseases.Plants (Basel, Switzerland) · 2026Review
- Geroprotective Potential ofNutrients · 2026Review
- Phytotherapeutic Potential of Medicinal Plants for Atopic Dermatitis:Biomolecules & therapeutics · 2026Review
- Article
- Targeted Extracellular Vesicles Deliver Asiaticoside to Inhibit AURKB/DRP1-Mediated Mitochondrial Fission and Attenuate Hypertrophic Scar Formation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Botanical and Upcycled Bioactives for Advanced Topical Formulations: Mechanistic Pathways, Cutaneous Delivery, and Sustainability-by-Design.Pharmaceutics · 2026Review
- Phytochemical profiling of Thai Centella asiatica: identification of new polyacetylene glucosides and analytical considerations in HPLC-UV analysis of triterpenoids.Journal of natural medicines · 2026Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.